华森制药 (002907)

Chongqing Pharscin Pharmaceutical Co., Ltd.

ASZ

Tags

Artificial Intelligence (AI)Generic DrugsNew Insurance HoldingsWeight Loss DrugsInnovative DrugsPharmaceutical ManufacturingIndustrial InternetHelicobacter PyloriVitaminsHepatitis ConceptShareholder Reduction

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 41759.63
  • Circulating A-Shares(W): 29991.45
  • Earnings Per Share(RMB): 0.1735
  • Net Assets Per Share(RMB): 4.0440
  • Operating Revenue(W RMB): 62591.20
  • Total Profit(W RMB): 8954.61
  • Net Profit Attributable to Parent(W RMB): 7245.56
  • Net Profit Growth Rate(%): -2.84
  • Weighted Return on Equity(%): 4.3100
  • Operating Cash Flow Per Share(RMB): 0.0590
  • Undistributed Profit Per Share(RMB): 1.7208
  • Capital Reserve Per Share(RMB): 1.0804

2. Main Business

The main business covers:

  • Research, production and sales of Chinese patent medicines
  • Research, production and sales of chemical drugs

3. Company Basic Information

  • Company Name: Chongqing Pharscin Pharmaceutical Co., Ltd.
  • Listing Date: 2017-10-20
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 89, Middle Section of Huangshan Avenue, Yubei District, Chongqing
  • Website: www.pharscin.com
  • Company Profile: The company was established through the overall change of Huasen Co., Ltd. into a joint stock company. On July 30, 2015, the promoters signed the "Sponsor Agreement". According to the sponsor agreement, the promoters converted the audited net asset value of Huasen Co., Ltd. as of May 31, 2015, which was 320,571,845.36 yuan, into the company's share capital of 300 million yuan at a ratio of 1:0.9358, with a par value of 1 yuan per share, totaling 300 million shares. The remaining 20,571,845.36 yuan was used as the company's capital reserve. On July 30, 2015, Tongzhixinde issued the "Asset Appraisal Report for the Shareholding System Reform Project of Chongqing Huasen Pharmaceutical Co., Ltd." (Tongzhixinde Pingbao Zi [2015] No. 146), confirming that as of May 31, 2015, the assessed net asset value of Huasen Co., Ltd. was 32,057.19 million yuan, with an appraised value of 37,576.73 million yuan, an increase of 5,519.54 million yuan, and an appreciation rate of 17.22%. On August 19, 2015, Dahua Certified Public Accountants issued the Dahua Yan Zi [2015] No. 000816 "Capital Verification Report" for the overall change of Huasen Co., Ltd., verifying that the above-mentioned capital contributions of the promoters had been fully paid in place. On August 25, 2015, the company completed the industrial and commercial change registration at the Rongchang District Branch of the Chongqing Administration for Industry and Commerce and obtained the "Business License" with registration number 500226000003922, with a registered capital of 300 million yuan.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chengdu Local Construction Mechanization Engineering Co., Ltd. General Legal Person 16304.43 54.36
2 Shanghai Tiancheng Investment Management Co., Ltd. - Tiancheng Tianli No.1 Private Securities Investment Fund Private Securities Investment Fund 587.80 1.96
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 262.07 0.87
4 Dajia Asset Management - Minsheng Bank - Dajia Asset Qiji Changhong No.6 Mixed Asset Management Product Asset Management Plan 106.70 0.36
5 Dajia Life Insurance Co., Ltd. - Dividend Product Insurance 82.43 0.27
6 J.P.Morgan Securities PLC - Own Funds QFII 74.76 0.25

5. Concept Sectors

  • Vitamins
  • Artificial Intelligence
  • Industrial Internet
  • Generic Drugs
  • Helicobacter Pylori
  • Hepatitis Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • Shareholder Reduction
  • Insurance New Entry

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information